Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 2 trials

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 3
1(50.0%)
2Total
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT06182774Phase 3Recruiting

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Role: collaborator

NCT06485076Not ApplicableRecruiting

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Role: collaborator

All 2 trials loaded